Revelation Biosciences Inc (REVB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.97 (+2.31%), Market cap $0.00B, 52-week low–high $0.65 ~ $3.09.
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therap
Financial statements, price targets, institutional (13F) holdings and related news for Revelation Biosciences Inc are updated in real time on BlackAll Trade.
Revelation Biosciences Inc trades at $0.97 (+2.31%). Real-time quotes and charts are available on BlackAll Trade.
Revelation Biosciences Inc has a market cap of about $0.00B.
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product can